Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration.
Breton M AskenPeter A LjubenkovAdam M StaffaroniKaitlin B CasalettoLawren VandevredeYann CobigoJulio C Rojas-RodriguezKatherine P RankinJohn KornakHilary HeuerJudy ShigenagaBrian S ApplebyAndrea C BozokiKimiko Domoto-ReillyNupur GhoshalEdward HueyIrene LitvanJoseph C MasdeuMario F MendezBelen PascualPeter PressmanMaria Carmela TartagliaWalter KremersLeah K ForsbergBrad F BoeveAdam L BoxerHowie J RosenJoel H Kramernull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Systemic proinflammatory protein measurement, particularly TNFα, may improve clinical prognosis in autosomal dominant FTLD pathogenic variant carriers who are not yet exhibiting severe impairment. Integrating TNFα with markers of neuronal dysfunction like NfL could optimise detection of impending symptom conversion in asymptomatic pathogenic variant carriers and may help personalise therapeutic approaches.